Belsomra (Suvorexant) Cost in South Carolina: Prices, Insurance, and Savings in 2026

What Belsomra Actually Costs at South Carolina Pharmacies

The sticker price and the real price are not the same drug. Merck lists Belsomra at $340 per month, a figure that appears on pharmacy shelf tags and insurance explanation-of-benefits forms. Almost nobody pays that amount. Across South Carolina retail pharmacies in 2026, the average cash-pay price lands around $85 per month for a 30-tablet supply.

Prices vary by pharmacy, city, and whether you use a discount tool. In the original Herring et al. trial published in The Lancet Neurology (N=254 in the suvorexant arm), suvorexant 40 mg and 20 mg both improved sleep efficiency and reduced wake-after-sleep-onset compared with placebo over four weeks 1. The FDA ultimately approved doses of 5 mg, 10 mg, 15 mg, and 20 mg, with 10 mg as the recommended starting dose for most adults 2. Both the 10 mg and 20 mg tablets cost the same per unit at retail, so dose escalation does not change your monthly bill.

Large chain pharmacies in Columbia, Charleston, and Greenville tend to price Belsomra within $10 of one another when you pay cash. Independent pharmacies sometimes run $5 to $15 higher. Costco and pharmacy discount clubs occasionally post prices below the $85 average, though availability depends on the location stocking the brand product.

South Carolina Medicaid and Belsomra Coverage

South Carolina Medicaid does not cover Belsomra. The state's preferred drug list directs insomnia treatment toward generic alternatives: zolpidem (generic Ambien), eszopiclone (generic Lunesta), and trazodone used off-label for sleep. If a prescriber believes a dual orexin receptor antagonist is medically necessary, a prior authorization request can be submitted to the South Carolina Department of Health and Human Services, but approval rates for brand-only DORAs remain low when cheaper formulary options have not been tried first.

The American Academy of Sleep Medicine's 2017 clinical practice guideline recommended suvorexant as one of several pharmacologic options for sleep-onset and sleep-maintenance insomnia in adults 3. That recommendation gives prescribers clinical backing for a prior authorization appeal. A denial letter from SC Medicaid can be appealed through the state's fair hearing process within 30 days.

For SC Medicaid enrollees who cannot access Belsomra, cognitive behavioral therapy for insomnia (CBT-I) is covered and is recommended as first-line treatment by both the AASM and the American College of Physicians 4. CBT-I produces durable improvements in sleep efficiency without ongoing medication costs.

Private Insurance Coverage in South Carolina

Most commercial insurance plans in South Carolina place Belsomra on a non-preferred brand tier (Tier 3 or Tier 4), which means higher copays and often a prior authorization requirement. BlueCross BlueShield of South Carolina, the state's largest insurer, typically requires step therapy: patients must document an inadequate response to or intolerance of at least one generic sleep agent before Belsomra gets approved.

Copays on a Tier 3 formulary position generally run $50 to $75 per month after the deductible is met. On a Tier 4 or specialty tier, coinsurance of 25% to 40% applies, which could push costs above the $85 cash-pay price. In those cases, paying cash with a discount card may actually cost less than using insurance.

A 2020 analysis in the Journal of Managed Care & Specialty Pharmacy found that prior authorization requirements for brand insomnia medications reduced plan spending but increased time-to-therapy by a median of 11 days 5. For patients with severe insomnia, that delay is clinically significant. Prescribers can expedite coverage by documenting failed trials of zolpidem and eszopiclone in the prior authorization submission, including specific adverse effects or lack of efficacy.

The Merck Savings Card and How It Works in South Carolina

Merck offers a manufacturer savings card for Belsomra that reduces out-of-pocket costs for commercially insured patients. Eligible patients may pay as little as $0 to $40 per month, depending on insurance plan structure. The card is not available to patients enrolled in Medicare, Medicaid, TRICARE, or any other federal or state government-funded healthcare program.

To use the card in South Carolina, patients activate it online or by phone, then present it at any participating pharmacy alongside their insurance card. The savings card covers the gap between the insurance copay and the promotional price floor. Annual caps apply; most manufacturer copay cards cap at $1,500 to $3,000 in annual assistance.

One limitation: high-deductible health plans. If you have not yet met your deductible, the pharmacy processes the claim at the full negotiated rate. The savings card then covers a portion, but the amount applied to your deductible depends on whether your insurer counts manufacturer copay assistance toward deductible accumulation. South Carolina does not currently have a state law mandating copay accumulator protections, so some plans may not credit savings-card payments toward your deductible or out-of-pocket maximum.

Compounded Suvorexant in South Carolina

Compounded suvorexant is available through licensed 503A compounding pharmacies in South Carolina. Under federal law (Drug Quality and Security Act, Section 503A), a licensed pharmacist may compound a medication based on an individual patient prescription when a valid prescriber-patient relationship exists 6. South Carolina's Board of Pharmacy regulates 503A compounding pharmacies operating within the state.

Compounded formulations may differ from the brand product in excipients, capsule form, or available dosing increments. A compounding pharmacy could prepare suvorexant in a dose not commercially available (for example, 7.5 mg or 12.5 mg), which gives prescribers more flexibility in dose titration.

Pricing for compounded suvorexant varies by pharmacy. Some 503A pharmacies in South Carolina offer compounded sleep formulations at prices below the $85 retail average for brand Belsomra. Patients should confirm that the compounding pharmacy sources suvorexant from an FDA-registered bulk drug substance supplier and holds a current South Carolina Board of Pharmacy compounding permit.

One clinical consideration: compounded products do not undergo the same bioequivalence testing as FDA-approved tablets. Dr. Andrew Krystal, a sleep researcher at UCSF and co-author on multiple DORA trials, has noted that "the orexin receptor antagonist class works within a narrow therapeutic window, and dose precision matters for balancing efficacy against next-morning residual effects" 7. Patients switching from brand Belsomra to a compounded formulation should monitor for changes in onset, duration, or morning drowsiness.

Telehealth Prescribing of Belsomra in South Carolina

South Carolina permits telehealth prescribing of Belsomra. The state updated its telemedicine laws in 2021, allowing prescribers to establish a patient relationship and prescribe Schedule IV controlled substances (suvorexant is Schedule IV) via audio-video telehealth visits. An initial in-person visit is not required.

This matters for patients in rural South Carolina counties where board-certified sleep medicine physicians are scarce. According to the AASM's 2023 workforce analysis, South Carolina has fewer than 3 sleep medicine physicians per 100,000 adults, below the national average of 3.7 8. Telehealth closes that gap.

HealthRX and other telehealth platforms can evaluate patients for insomnia, review prior medication trials, and prescribe suvorexant with the prescription sent electronically to a South Carolina pharmacy for pickup or mail delivery. A telehealth visit also provides the documentation needed for insurance prior authorization submissions.

The DEA's updated telemedicine prescribing rules (effective 2025) require that the prescriber be registered in a state where the patient is located or where the prescriber holds a DEA registration 9. South Carolina-licensed prescribers with active DEA registrations can prescribe suvorexant to SC patients without restriction.

How Suvorexant Compares to Alternatives on Cost

Belsomra is not the only option for insomnia, and cost differences across the class are substantial.

Generic zolpidem (immediate-release) costs $4 to $15 per month at most South Carolina pharmacies. Generic eszopiclone runs $15 to $30. Trazodone, used off-label at 25 to 100 mg for sleep, costs under $10 per month. These are all generic, Tier 1 formulary drugs covered by SC Medicaid and virtually every commercial plan.

Within the DORA class, lemborexant (Dayvigo, Eisai) is the main competitor. Dayvigo's list price is comparable to Belsomra's, and its SC retail cash price runs approximately $90 to $110 per month. Dayvigo is also not covered by SC Medicaid.

A pooled analysis of DORA trials published in JAMA Network Open (2022) found that both suvorexant and lemborexant significantly reduced wake-after-sleep-onset versus placebo, with no statistically significant difference between the two agents on that outcome measure 10. If cost is the deciding factor between the two DORAs, suvorexant's lower average cash price in South Carolina gives it a modest edge.

For patients considering whether a DORA is worth the premium over generics, the clinical question is mechanism. Suvorexant blocks orexin-A and orexin-B signaling, reducing the wake drive rather than sedating the brain 1. This produces a different side-effect profile: less respiratory depression risk than benzodiazepine receptor agonists, which may matter for patients with mild obstructive sleep apnea. A post-hoc analysis of suvorexant trial data showed no worsening of apnea-hypopnea index in patients with mild to moderate OSA 11.

Discount Programs and Manufacturer Assistance

Beyond the Merck savings card, several pathways reduce Belsomra costs for South Carolina patients:

Merck Patient Assistance Program (Merck Helps). For uninsured or underinsured patients with household income below 400% of the federal poverty level, Merck provides Belsomra at no cost through its patient assistance program. Application requires income documentation and a prescriber's signature. Processing takes 4 to 6 weeks.

Pharmacy discount cards. GoodRx, RxSaver, and similar aggregators negotiate discount pricing with SC pharmacies. These cards are free, require no insurance, and can bring Belsomra below $80 at select locations. Prices change weekly, so checking multiple platforms before filling is worth the two minutes.

Mail-order pharmacies. Some patients save 10% to 15% by using mail-order services that ship 90-day supplies. Insurance plans with mail-order preferred benefits may offer lower copays for 90-day fills compared with three separate 30-day retail fills. South Carolina does not restrict mail-order delivery of Schedule IV medications.

340B pharmacies. Federally qualified health centers (FQHCs) and certain hospitals in South Carolina participate in the 340B Drug Pricing Program, which provides outpatient drugs at significantly reduced prices. Patients receiving care at a 340B-eligible site may access Belsomra at a fraction of retail cost. South Carolina has over 30 FQHC sites across the state 12.

When to Ask Your Prescriber About Switching

Not every patient with insomnia needs a DORA, and not every DORA patient needs to stay on one indefinitely. The AASM recommends reassessing insomnia pharmacotherapy every 4 to 8 weeks 3. If Belsomra is working and you can afford it, there is no clinical reason to switch based on cost alone. If cost is a barrier, a prescriber can transition you to a generic alternative with a structured taper and follow-up visit.

Suvorexant at 10 mg or 20 mg is taken once nightly, within 30 minutes of bedtime, with at least 7 hours of planned sleep remaining. Taking it with a high-fat meal delays onset by approximately 1.5 hours 2. Patients paying out of pocket should know that the 10 mg and 20 mg tablets cost the same per unit, so starting at the lower dose does not save money but does reduce the risk of next-morning somnolence, which occurred in 7% of patients on suvorexant 20 mg versus 3% on placebo in the phase III registration trials 1.